Head and Neck Squamous Cell Carcinoma (HNSCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Head and Neck Squamous Cell Carcinoma (HNSCC) presents a multifaceted array of malignancies, creating formidable challenges for medical practitioners. The majority of patients receive diagnoses at an advanced local disease stage, necessitating treatment regimens that encompass surgery, chemotherapy, and radiotherapy. Regrettably, approximately 50% of these individuals will undergo disease recurrence. In cases of recurrent or metastatic HNSCC, the prognosis is notably grim, with a median survival rate ranging from 12 to 15 months despite treatment efforts. Head and neck cancer stands as the seventh most prevalent cancer globally, constituting 3% of all cancer cases, with an annual incidence of roughly 900,000 new cases and half a million fatalities. Human papillomavirus (HPV) infection is now recognized as the primary causative factor for HNSCC, particularly in the oropharynx (OPSCC), responsible for approximately 60-70% of OPSCC cases in the United States. HPV-positive (HPV+) HNSCC exhibits distinct disparities in both epidemiology and pathophysiology when compared to HPV-negative (HPV-) or HPV-unrelated HNSCC. Demographically, patients with HPV+ OPSCC tend to be younger males, typically diagnosed in their 40s to 50s and are often non-smokers or light smokers. HPV infection is characterized by a latency period of 10-30 years between the initial infection and the clinical manifestation of HPV+ OPSCC.

Thelansis’s “Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Head and Neck Squamous Cell Carcinoma (HNSCC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Head and Neck Squamous Cell Carcinoma (HNSCC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Head and Neck Squamous Cell Carcinoma (HNSCC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Head and Neck Squamous Cell Carcinoma (HNSCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033